What's in a risk factor? "He who strikes the ball"

Diabetes and Metabolism

Volumn 29, Issue 1, 2003, Pages 6-13

  Capron, L ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Cause; Coronary artery disease; Epidemiology; Risk factor; Risk marker

Indexed keywords

ADULT; CORONARY ARTERY DISEASE; DISEASE MARKER; HUMAN; INCIDENCE; PREVALENCE; REVIEW; RISK FACTOR;

EID: 0037301290     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70001-0     Document Type: Review

References (36)

1. Keys A. Seven Countries: A multivariate analysis of death and coronary heart disease. Cambridge, Harvard University Press, 1980.
2. Stamler J. The concept of cardiovascular risk factors. Cardiovasc Risk Factors, 1990, 1, 4-7.
3. Burch PRJ. Ischæmic heart disease: epidemiology, risk factors and cause. Cardiovasc Res, 1980, 14, 307-38.
4. nd edition, 1986.
5. Pais P, Pogue J, Gerstein H, et al. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet, 1996, 348, 358-63.
6. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet, 2002, 359, 431-4.
7. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet, 2002, 359, 341-5.
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-44.
9. Ducimetière P, Richard J, Claude JR, Warnet JM, Groupe d'Étude sur l'Épidémiologie de l'Athérosclérose (GRÉA). Les cardiopathies ischémiques: incidence et facteurs de risque - L'Étude prospective parisienne. Paris, Éditions INSERM, 1981.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-9.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
12. st edition, 1879).
13. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol, 1998, 81, 7B-12B.
14. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis, 1981, 40, 1-52.
15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995, 333, 1301-7.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996, 335, 1001-9.
17. The Long-Term Intervention with Pravastatin in Ischæmic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range ofinitial cholesterol levels. N Engl J Med, 1998, 339, 1349-57.
18. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 1998, 279, 1615-22.
19. Palinski, W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol, 2001, 21, 3-5.
20. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency ofcitation and outcome. BMJ, 1992, 305, 15-9.
21. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 1990, 335, 827-38.
22. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, 2001, 358, 1305-15.
23. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol, 1995, 75, 894-903.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylireas or insulin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
25. Ebrahim S, Davey Smith G. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ, 1997, 314, 1666-74.
26. Sprengel K. Histoire de la médecine depuis son origine jusqu'au dixneuvième siècle (traduite de l'allemand sur la seconde édition, par AJL Jourdan). 1815, Paris, Deterville et Desoer.
27. Clinical Synthesis Panel on HRT. Hormone replacement therapy. Lancet, 1999, 354, 152-5.
28. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, 605-13.
29. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med, 2000, 343, 522-9.
30. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-33.
31. Skegg DCG. Hormone therapy and heart disease after the menopause. Lancet, 2001, 358, 1196-7.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 23-33.
33. Hooper L, Summerbell CD, Higgins JPT, et al. Dietary intake and prevention of cardiovascular disease: systematic review. BMJ, 2001, 322, 757-63.
34. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? BMJ, 1996, 312, 731-6.
35. Capron L. Étiologie de l'athérosclérose. Rev Prat, 1999, 49, 2100-3.
36. Danesh J, Whincup P, Walker, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ, 2000, 321, 199-204.